INT96132

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 2001
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 10
Total Number 10
Disease Relevance 6.99
Pain Relevance 1.24

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (F10) extracellular region (F10) plasma membrane (F10)
Anatomy Link Frequency
plasma 3
monocyte 1
F10 (Homo sapiens)
Pain Link Frequency Relevance Heat
Angina 9 99.64 Very High Very High Very High
Duloxetine 1 97.76 Very High Very High Very High
Inflammation 22 95.12 Very High Very High Very High
Morphine 1 93.60 High High
pregabalin 1 89.24 High High
cytokine 7 88.80 High High
aspirin 8 83.72 Quite High
cva 65 71.72 Quite High
ischemia 10 50.00 Quite Low
Inflammatory response 6 46.20 Quite Low
Disease Link Frequency Relevance Heat
Benign Prostatic Hypertrophy 115 100.00 Very High Very High Very High
Prostate Cancer 45 100.00 Very High Very High Very High
Cv General 3 Under Development 33 99.64 Very High Very High Very High
Myocardial Infarction 38 98.76 Very High Very High Very High
Heparin-induced Thrombocytopenia 7 97.44 Very High Very High Very High
INFLAMMATION 28 95.12 Very High Very High Very High
Thrombosis 51 91.48 High High
Disease 18 88.84 High High
Recurrence 6 81.84 Quite High
Hemorrhage 32 81.44 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In unstable angina patients, plasma levels of TF, TFPI and TFPI/FXa were more efficiently reduced by adjunct ticlopidine therapy compared with adjunct coumadin/dipyridamole.
Gene_expression (levels) of FXa in plasma associated with angina
1) Confidence 0.58 Published 2003 Journal Blood Coagul. Fibrinolysis Section Abstract Doc Link 12945880 Disease Relevance 0.39 Pain Relevance 0.46
Fondaparinux, a pentasaccharide, is a synthetic indirect inhibitor of Factor Xa (FXa).
Gene_expression (synthetic) of FXa
2) Confidence 0.53 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2879296 Disease Relevance 1.02 Pain Relevance 0.03
Those expressed extracellularly and with an average expression level at least three-fold greater in BPH RNA pools than in the prostate cancer RNA pools included: CDH13, CHRNB1, COL4A5, EFEMP2, EMP3, F10 (16-fold), FGF2, FGFBP1 (10-fold), IGF1, IGF2 (18-fold), LIPG, RARB, SGCA, SGCD, TGFB1, TGFB3 (14-fold), TGFBR2 and TIMP2 of the “high in BPH, moderate in prostate cancer” group; SMOC1 (26-fold) in the “high in BPH, low in prostate cancer” group; and SCGB3A1 (15-fold) and SCGB1A1 (14-fold) in the “moderate in BPH, low in prostate cancer” group.


Gene_expression (expressed) of F10 associated with benign prostatic hypertrophy and prostate cancer
3) Confidence 0.50 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2793011 Disease Relevance 2.45 Pain Relevance 0
Video images were recorded following injection of OG488-labeled fibrinogen, prothrombin, FXa or anti-CD41 (integrin ?
Gene_expression (labeled) of FXa
4) Confidence 0.46 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2861630 Disease Relevance 0.29 Pain Relevance 0
TF proteolytic activity was measured with spectrozyme factor Xa (FXa), TF and TFPI-1 surface expression on monocytes by flow cytometry, RNA expression in whole blood by reverse transcription-polymerase chain reaction, and concentrations of plasma prothrombin fragments F(1 + 2) by immunoassay.
Gene_expression (expression) of FXa in plasma
5) Confidence 0.26 Published 2001 Journal Blood Section Abstract Doc Link 11389008 Disease Relevance 0.72 Pain Relevance 0.10
TF proteolytic activity was measured with spectrozyme factor Xa (FXa), TF and TFPI-1 surface expression on monocytes by flow cytometry, RNA expression in whole blood by reverse transcription-polymerase chain reaction, and concentrations of plasma prothrombin fragments F(1 + 2) by immunoassay.
Gene_expression (expression) of factor Xa in plasma
6) Confidence 0.26 Published 2001 Journal Blood Section Abstract Doc Link 11389008 Disease Relevance 0.73 Pain Relevance 0.10
FXa generation by monocytes of patients with AMI increased 53.6% +/- 9% in the presence of polyclonal antibodies to TFPI-1, indicating that cell-associated TFPI-1 inhibits monocyte TF activity.
Gene_expression (generation) of FXa in monocyte associated with myocardial infarction
7) Confidence 0.18 Published 2001 Journal Blood Section Abstract Doc Link 11389008 Disease Relevance 0.71 Pain Relevance 0.07
Alemtuzumab, Atomoxetine hydrochloride; BioMatrix Flex drug-eluting stent, Botulinum toxin type B, Brivaracetam, Cannabidiol, Carisbamate, Cetuximab, Ciclesonide, Daptomycin, Darunavir, Duloxetine hydrochloride, Ecallantide, Enfuvirtide, Etravirine, Everolimus-eluting coronary stent, Ezetimibe; Fluticasone furoate, FX-125L; Ghrelin (human); Idraparinux sodium; Lersivirine, Levocetirizine dihydrochloride, Levodopa/carbidopa/entacapone, Liposomal doxorubicin, LNCaP/IL-2/IFN-gamma; Morphine hydrochloride; Natalizumab; Olmesartan medoxomil; Paclitaxel-eluting stent, Perampanel, Pertuzumab, Pregabalin; Rasagiline mesilate, Rimonabant, Riociguat, Roflumilast, Rosuvastatin calcium, Rufinamide; Sirolimus-eluting stent; Tadalafil, Telavancin hydrochloride, Telmisartan/amlodipine besilate, Tenofovir disoproxil fumarate/emtricitabine, Tolvaptan; Valganciclovir hydrochloride, Vinflunine; Zotarolimus-eluting stent.
Gene_expression (furoate) of FX-125L associated with pregabalin, duloxetine and morphine
8) Confidence 0.17 Published 2010 Journal Methods Find Exp Clin Pharmacol Section Abstract Doc Link 20401351 Disease Relevance 0 Pain Relevance 0.23
This complex has been demonstrated as being critical for presenting Factor VIIa and Factor Xa to PARs on the cell surface.
Gene_expression (presenting) of Factor Xa
9) Confidence 0.07 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2211395 Disease Relevance 0.59 Pain Relevance 0.17
Anti-factor Xa analysis
Gene_expression (analysis) of Anti-factor Xa
10) Confidence 0.04 Published 2009 Journal Thromb J Section Body Doc Link PMC2777119 Disease Relevance 0.09 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox